JLK notches 7th FDA nod for AI stroke detection as 8 more line up in US push

JLK is sharpening its focus on the U.S. market, landing FDA 510(k) clearance for JLK-SDH, its AI-powered subdural hemorrhage (SDH) detection tool. The approval, announced Wednesday, brings the Korean medical AI developer’s FDA-cleared portfolio to seven, a milestone as the company expands its AI-driven stroke diagnostics into hospitals nationwide.

JLK isn’t slowing down. The company is preparing eight more FDA submissions this year, a spokesperson said, while also seeking approvals in Japan, where its team is attending Medical Japan in Osaka this week.

JLK secures its 7th FDA nod for AI stroke detection, with 8 more filings ahead as it accelerates U.S. expansion. (Credit: JLK)

For emergency physicians, every second matters when diagnosing SDH, a potentially fatal brain bleed that can be difficult to detect on CT scans. JLK says its AI solution helps overcome those challenges, analyzing scans 30 percent faster than standard methods, potentially saving lives by catching hemorrhages before they worsen.

The technology arrives at a time when hospitals are grappling with high patient volumes, particularly in the U.S., where millions of traffic accidents send head trauma patients into emergency rooms every year. JLK aims to make its AI-powered stroke detection a critical tool in triage and decision-making.

The approval adds to JLK’s broader push in AI-driven stroke detection. Just last week, the company also secured FDA clearance for JLK-AILink, an AI-powered imaging platform that integrates stroke diagnostics across CT, CTA, CTP, and MRI. Instead of rolling out piecemeal AI tools, JLK is betting on a more integrated approach, one it says will cut hospital maintenance costs while maximizing its own profitability.

The AI stroke detection space is getting crowded, with Israeli firms Nanox.AI and Aidoc, along with India’s Qure.ai, already competing for market share. But JLK is leaning on its deep clinical partnerships, including collaborations with Harvard affiliated hospitals, Stanford University, and the University of São Paulo, to set itself apart.

The company says its AI has been trained on a diverse range of patient data, improving accuracy across different ethnicities and reducing bias in diagnostic outcomes. “We have conducted clinical trials on both Asian and Western patients, ensuring our AI is trained on broad, unbiased datasets,” the JLK spokesperson said

CEO Kim Dong-min framed the latest FDA clearance as a validation of JLK’s broader AI platform. “Through clinical validation with leading institutions like Harvard, we’ve proven our AI’s reliability for real-world use. Our AI solution for subdural hemorrhage detection will allow physicians to act faster in high-stakes emergency settings, improving patient outcomes,” Kim said.

JLK is also integrating its AI into SNAPPY, a mobile app that alerts physicians when SDH is detected on non-contrast CT scans. With prognosis heavily dependent on how quickly treatment begins, the company emphasized that reducing diagnosis time could directly improve survival rates.